Statsols Blog

Statsols

Recent Posts by Statsols:

Top 10 Corporate Clinical Trial Sponsors of 2016

Following on from our previous blog post, The Most Popular Clinical Trial Drugs of 2016, we thought it would be a good idea to take a closer look at the Top 10 Corporate Clinical Trial Sponsors of 2016.

In this post, we explore these Top 10 companies, looking at their developmental histories as well as the drugs they have developed and the number of subjects required for their 2016 registered trials.

Topics: Power & Sample Size Clinical Trials Clinical Trial Sponsors Top10

Wider Integration of Cost Considerations in Sample Size

In part 3/3 of this mini series, Head of Statistics at Statsols - Ronan Fitzpatrick - examines key trends in sample size determination which are being felt in trial design.

Topics: Power & Sample Size cost consideration, integration

The Effect of Adaptive Trials and Sample Size Re-estimation

In part 2/3 of this mini series, Head of Statistics at Statsols - Ronan Fitzpatrick - examines key trends in sample size determination which are being felt in trial design.

Topics: Power & Sample Size adaptive trials sample size restimation

Integrating Uncertainty in Parameter Estimates

In part 1/3 of this mini series, Head of Statistics at Statsols - Ronan Fitzpatrick - examines key trends in sample size determination which are being felt in trial design.

Topics: Power & Sample Size Parameter Estimates

Most Popular Clinical Trial Drugs of 2016

Currently there are over 205,000 registered clinical trials underway throughout the globe. In 2016 over 14,000 new trials were initiated and we thought it would be useful to look at the top drugs under investigation for the year just past.

Topics: Power & Sample Size Phase III Failure

15 Ways to Reduce Sample Size In Clinical Trials

How do you reduce sample size in clinical trials? Reducing sample size without losing power can be accomplished in one of three principles. This paper examines these methods and demonstrates 15 ways to reduce sample size in clinical trials.

Topics: Power & Sample Size Clinical Trials Reduce Sample Size

Why do phase III clinical trials fail?

Why do Phase III clinical trials fail and how can we improve them? Dr. Grignolo, PhD, Corporate Vice President of PAREXEL International, the multinational life sciences consulting firm, recently examined this issue in a paper titled: Phase III Trial Failures: Costly, But Preventable.

We have reviewed this journal and brought you the primary findings as they appeared in Applied Clinical Trials Volume 25, Issue 8 and also on appliedclinicaltrialsonline.com.

Topics: Power & Sample Size Phase III Failure

What is the difference between Superiority vs. Equivalence vs. Non-inferiority in clinical trial design

The terms superiority, equivalence and non-inferiority are used frequently in publications on clinical trials. To someone starting out in clinical research these three terms and their precise meaning can be quite difficult to grasp. Indeed even experienced researchers have trouble getting their head around these hypotheses. So, what do these terms mean?

Topics: Introduction to Sample Size Clinical Trials nQuery